Disrupting resistance to EGFR-specific tyrosine kinase inhibitors in TP53-mutated lung carcinoma cell lines by proteasome inhibition

被引：0
|
作者：
Orth, Franziska
Schaefer, Benjamin
Harsch, Annika
Weller, Sandra
Beigl, Tobias
Barber, Lynn
Kopp, Hans-Georg
Essmann, Frank
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2532
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2532
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
    Jung, Sangyong
    Kim, Dong Ha
    Choi, Yun Jung
    Kim, Seon Ye
    Park, Hyojeong
    Lee, Hyeonjeong
    Choi, Chang-Min
    Sung, Young Hoon
    Lee, Jae Cheol
    Rho, Jin Kyung
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [42] Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
    Sangyong Jung
    Dong Ha Kim
    Yun Jung Choi
    Seon Ye Kim
    Hyojeong Park
    Hyeonjeong Lee
    Chang-Min Choi
    Young Hoon Sung
    Jae Cheol Lee
    Jin Kyung Rho
    Scientific Reports, 11
  • [43] Identification of novel mechanisms of resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
    de Bruin, Elza C.
    Cowell, Catherine F.
    Howell, Michael
    Varmus, Harold E.
    Politi, Katerina
    Downward, Julian
    CANCER RESEARCH, 2011, 71
  • [44] Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer
    Kashima, Yukie
    Shibahara, Daisuke
    Suzuki, Ayako
    Muto, Kyoko
    Kobayashi, Ikei S.
    Plotnick, David
    Udagawa, Hibiki
    Izumi, Hiroki
    Shibata, Yuji
    Tanaka, Kosuke
    Fujii, Masanori
    Ohashi, Akihiro
    Seki, Masahide
    Goto, Koichi
    Tsuchihara, Katsuya
    Suzuki, Yutaka
    Kobayashi, Susumu S.
    CANCER RESEARCH, 2021, 81 (18) : 4835 - 4848
  • [45] Elucidating mechanisms of resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC)
    Pao, William
    Miller, Vincent A.
    Kris, Mark G.
    Varmus, Harold E.
    ANNALS OF ONCOLOGY, 2004, 15 : 4 - 4
  • [46] Ferritinophagy mediates adaptive resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
    Wang, Hui
    Hu, Qianfan
    Chen, Yuzhong
    Huang, Xing
    Feng, Yipeng
    Shi, Yuanjian
    Li, Rutao
    Yin, Xuewen
    Song, Xuming
    Liang, Yingkuan
    Zhang, Te
    Xu, Lin
    Dong, Gaochao
    Jiang, Feng
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [47] RICTOR signaling modulates the activity of EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutated non-small cell lung cancer (NSCLC)
    Fan, Ni
    Zou, Yiyu
    Halmos, Balazs
    Perez-Soler, Roman
    Cheng, Haiying
    CANCER RESEARCH, 2019, 79 (13)
  • [48] Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors
    Karima Saboundji
    Jean-Bernard Auliac
    Maurice Pérol
    Géraldine François
    Henri Janicot
    Marie Marcq
    Catherine Dubos-Arvis
    Aldo Renault
    Florian Guisier
    Luc Odier
    Radj Gervais
    Christos Chouaïd
    Targeted Oncology, 2018, 13 : 501 - 507
  • [49] Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors
    Saboundji, Karima
    Auliac, Jean-Bernard
    Perol, Maurice
    Francois, Geraldine
    Janicot, Henri
    Marcq, Marie
    Dubos-Arvis, Catherine
    Renault, Aldo
    Guisier, Florian
    Odier, Luc
    Gervais, Radj
    Chouaid, Christos
    TARGETED ONCOLOGY, 2018, 13 (04) : 501 - 507
  • [50] Short-term responders of non-small cell lung cancer patients to EGFR tyrosine kinase inhibitors display high prevalence of TP53 mutations and primary resistance mechanisms
    Fan, Y.
    Xu, Y.
    Tong, X.
    Yan, J.
    Wu, X.
    Shao, Y. W.
    ANNALS OF ONCOLOGY, 2018, 29
12345